Wellington Management Group LLP Makes New Investment in Capricor Therapeutics Inc (NASDAQ:CAPR)

Wellington Management Group LLP acquired a new position in Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 40,959 shares of the biotechnology company's stock, valued at approximately $565,000. Wellington Management Group LLP owned about 0.09% of Capricor Therapeutics at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. California State Teachers Retirement System increased its position in shares of Capricor Therapeutics by 1,653.0% during the 4th quarter. California State Teachers Retirement System now owns 32,237 shares of the biotechnology company's stock valued at $445,000 after purchasing an additional 30,398 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in shares of Capricor Therapeutics during the 4th quarter valued at approximately $462,000. Voloridge Investment Management LLC bought a new position in shares of Capricor Therapeutics during the 4th quarter valued at approximately $1,678,000. Woodline Partners LP bought a new position in shares of Capricor Therapeutics during the 4th quarter valued at approximately $8,693,000. Finally, Two Sigma Investments LP increased its position in shares of Capricor Therapeutics by 223.6% during the 4th quarter. Two Sigma Investments LP now owns 119,047 shares of the biotechnology company's stock valued at $1,643,000 after purchasing an additional 82,254 shares during the last quarter. Institutional investors own 21.68% of the company's stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. Roth Capital initiated coverage on Capricor Therapeutics in a research report on Tuesday, May 20th. They set a "buy" rating and a $31.00 target price on the stock. Wall Street Zen lowered Capricor Therapeutics from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. HC Wainwright reiterated a "buy" rating and issued a $77.00 target price on shares of Capricor Therapeutics in a research note on Monday, March 17th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and issued a $30.00 target price on shares of Capricor Therapeutics in a research note on Wednesday, May 14th. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, Capricor Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $35.50.

Capricor Therapeutics Trading Down 5.4%

Shares of Capricor Therapeutics stock traded down $0.75 during trading on Wednesday, hitting $13.14. 3,226,091 shares of the stock traded hands, compared to its average volume of 1,803,399. The firm has a market cap of $600.20 million, a P/E ratio of -12.40 and a beta of 0.84. Capricor Therapeutics Inc has a 52-week low of $3.52 and a 52-week high of $23.40. The stock's fifty day simple moving average is $10.57 and its 200 day simple moving average is $12.86.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The biotechnology company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.20). Capricor Therapeutics had a negative net margin of 146.86% and a negative return on equity of 112.95%. The firm had revenue of $2.73 million for the quarter, compared to analysts' expectations of $3.16 million. During the same quarter in the prior year, the business posted ($0.31) EPS. As a group, equities analysts expect that Capricor Therapeutics Inc will post -1.21 EPS for the current year.

Capricor Therapeutics Profile

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.